• Explore /
  • Poster
  • / Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.

Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.

Abstract Poster

Authors

Piotr Wysocki

Piotr Jan Wysocki

Jagiellonian University Hospital, Kraków, Poland

Piotr Jan Wysocki , Maciej Tadeusz Lubaś , Mateusz Łobacz, , Ewa Kalinka-Warzocha , Piotr Tomczak , Michal Kwiatek , Iwona A. Lugowska , Martin Smakal , Dominik Chraniuk , Bohuslav Melichar , Beate Markiewicz-Bialek , Kasi V. Routhu , Prajak J. Barde , Ajit Nair

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT05002868

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3097)

DOI

10.1200/JCO.2023.41.16_suppl.3097

Abstract #

3097

Poster Bd #

295

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.

Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.

First Author: Piotr Jan Wysocki

First Author: Severine Guiu Lahaye

First Author: Ecaterina Elena Dumbrava

First Author: YunJung Kim